In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, analyst expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which analyst believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.’s Zontivity (vorapaxar), AstraZeneca’s Brilinta (ticagrelor), and Bayer and Janssen’s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.

In 2014, the PAD therapeutics market in China was worth approximately $93.7m. Generic anticoagulant drugs, primarily warfarin, will suffer a negative CAGR of approximately 10.15% as Xarelto and generic rivaroxaban begin to encroach on warfarin’s stake in the PAD market.

Browse Full Research Report With TOC:  http://www.radiantinsights.com/research/peripheral-artery-disease-china-drug-forecast-and-market-analysis-to-2024

Scope:
–    Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
–    Detailed information on the key drugs in China including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
–    Sales forecast for the top drugs in China from 2014-2024.
–    Analysis of the impact of key events as well the drivers and restraints affecting China PAD market.

Reasons to Buy:
–    Understand and capitalize by identifying products that are most likely to ensure a robust return
–    Stay ahead of the competition by understanding the changing competitive landscape for PAD.
–    Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
–    Make more informed business decisions from insightful and in-depth analysis of drug performance
–    Obtain sales forecast for drugs from 2014-2024 in China.

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s